Cheryl Enger

New England College of Optometry — United States

Medicine · Health Sciences

47h-index8.0kcitations132works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glaucoma and retinal disorders(18), Intraocular Surgery and Lenses(15), Retinal Diseases and Treatments(14), Retinal and Macular Surgery(10), Retinal Imaging and Analysis(10)

Publications131 total

Correction to: Development and Validation of ICD‑10‑CM‑based Algorithms for Date of Last Menstrual Period, Pregnancy Outcomes, and Infant Outcomes
Drug Safety·2023· 1 citedOpen Access
Development and Validation of ICD-10-CM-based Algorithms for Date of Last Menstrual Period, Pregnancy Outcomes, and Infant Outcomes
Drug Safety·2023· 20 citedOpen Access
Trends in COVID-19 patient characteristics in a large electronic health record database in the United States: A cohort study
PLoS ONE·2022· 7 citedOpen Access
Predictors of critical care, mechanical ventilation, and mortality among hospitalized patients with COVID-19 in an electronic health record database
BMC Infectious Diseases·2022· 17 citedOpen Access
Cardiovascular risk in users of mirabegron relative to users of antimuscarinic treatments for overactive bladder: Findings from a non-interventional, real-world data safety study
University of Southern Denmark Research Portal (University of Southern Denmark)·2021
Method used to identify adenomyosis and potentially undiagnosed adenomyosis in a large, U.S. electronic health record database
Pharmacoepidemiology and Drug Safety·2021· 9 cited
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
Drug Safety·2021· 19 citedOpen Access
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder
Current Medical Research and Opinion·2021· 5 citedOpen Access
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post‐authorization safety cohort study conducted in Europe and in the United States
Pharmacoepidemiology and Drug Safety·2021· 9 citedOpen Access
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder
Figshare·2021Open Access
Abstract 13154: Cardiovascular Risk in Users of Mirabegron Relative to Users of Antimuscarinic Treatments for Overactive Bladder: Findings From a Non-interventional, Real-world Data Safety Study
Circulation·2020
PD44-10 A STUDY OF CANCER OCCURRENCE IN USERS OF MIRABEGRON AND ANTIMUSCARINIC TREATMENTS FOR OVERACTIVE BLADDER
The Journal of Urology·2020
Measuring problem prescription opioid use among patients receiving long-term opioid analgesic treatment: development and evaluation of an algorithm for use in EHR and claims data
Journal of Drug Assessment·2020· 26 citedOpen Access
Supplementary Material for: Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data
Figshare·2020Open Access
Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data
Respiration·2020· 21 citedOpen Access
Identifying and classifying opioid‐related overdoses: A validation study
Pharmacoepidemiology and Drug Safety·2019· 63 citedOpen Access
Validating an algorithm for multiple myeloma based on administrative data using a SEER tumor registry and medical record review
Pharmacoepidemiology and Drug Safety·2019· 9 cited
A Survey of Patients’ Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications
Journal of General Internal Medicine·2019· 13 citedOpen Access
Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data
BMC Pulmonary Medicine·2019· 14 citedOpen Access
Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey
The Journal of Law Medicine & Ethics·2019· 10 cited
page 1 of 7Next →

Frequent Co-authors

Ronald G. Michels(5), Serge de Bustros(5), Bert M. Glaser(5), Douglas A. Jabs(4), Irvin P. Pollack(3), Thomas A. Rice(3), Guy M. McKhann(3), Louis M. Borowicz(3), Ola A. Selnes(3), James P. Dunn(3), Walter J. Stark(3), Andrew T. McAfee(3), John T. Thompson(2), Omofolasade Kosoko(2), Douglas Gaasterland(2), R G Michels(2), Alexander M. Walker(2), Maura A. Goldsborough(2), Michael Forman(2), Patricia M. Quinlan(2)